The Vigabatrin REMS Program is required by the FDA to make sure educated risk-benefit choices prior to launching treatment, and to make sure appropriate use vigabatrin while individuals are treated. It is not possible for your healthcare provider to recognize when vision loss will take place.
It is recommended that your healthcare provider test your (or your kid's) vision prior to or within 4 weeks after starting SABRIL and a minimum of every 3 months throughout therapy till SABRIL is quit. If you or your child have any side result that troubles you or that does not go away, inform your medical care company.
Inform your doctor if you are expectant or mean to obtain pregnant. If vision screening can not be done, your healthcare provider may continue prescribing SABRIL, but will not be able to watch for any type of vision loss. If vision tests are refrained regularly, your doctor might quit recommending SABRIL for you (or your child).